The future is now: Gene therapy to take flight in Europe

Print Friendly, PDF & Email
Nov RedWhiteDNALinkingUp GeneTherapyGlybera

After many years of crushed expectations, gene therapy could be close to a victory: a regulatory approval.

The European Medicines Agency has recommended approval of a gene therapy to treat a rare genetic disease, called lipoprotein lipase deficiency, which prevents people from digesting fat. The drug, called Glybera, created by Dutch-based company uniQure, had previously been rejected by the EMA three times.

This recommendation still requires approval by the European Commission, which is expected within three months. Many anticipate that the drug will be approved, due to the fact that the EC generally follows advice from the EMA.

If Glybera is indeed approved, it will be the first commercial gene therapy to win regulatory approval in the West. The only additional gene therapy drug commercially available is Gendicine, which is used in China to treat cancer.

It is still unclear whether or not uniQure will apply for FDA approval for US marketing.

Additional Resources:

Outbreak Featured
Infographic: Growing human embryos — How long should researchers watch human development play out in a dish?

Infographic: Growing human embryos — How long should researchers watch human development play out in a dish?

In May, the International Society for Stem Cell Research (ISSCR) released new guidelines that relaxed the 14-day rule, taking away ...
Are GMOs and pesticides threatening bees?

Are GMOs and pesticides threatening bees?

First introduced in 1995, neonicotinoids ...
glp menu logo outlined

Newsletter Subscription

* indicates required
Email Lists
glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.